This article has Open Peer Review reports available.
Expression and role of oncogenic miRNA-224 in esophageal squamous cell carcinoma
- Xiaoyan He†1, 2,
- Zhimei Zhang†1, 3,
- Ming Li1, 4,
- Shuo Li1,
- Lihua Ren1, 5,
- Hong Zhu1,
- Bin Xiao1 and
- Ruihua Shi1, 6Email author
© He et al. 2015
Received: 17 October 2014
Accepted: 27 July 2015
Published: 6 August 2015
Aberrant expression of miR-224 is associated with tumor development and progression. This study investigated the role of miR-224 in esophageal squamous cell carcinoma (ESCC) ex vivo and in vitro.
A total of 103 esophageal intraepithelial neoplasia, ESCC tissue specimens, and their matched distant normal tissues were collected to test miR-224 expression using qRT-PCR analysis. Western blot was used to quantify the level of PH domain leucine-rich repeat protein phosphatase 1 (PHLPP1) and PHLPP2 in ESCC tissues. Cell viability, apoptosis, invasion, and colony formation assays were used to assess the altered phenotypes of esophageal cancer cell lines after miR-224 expression or inhibition. A luciferase reporter assay was used to confirm miR-224 binding to PHLPP1 and PHLPP2 mRNA.
miR-224 was significantly overexpressed in esophageal intraepithelial neoplasia and ESCC tissues, while the expression of PHLPP1 and PHLPP2 proteins, the target genes of miR-224, was downregulated in ESCC tissues. miR-224 expression was associated with advanced clinical TNM stage, pathologic grade, and the level of PHLPP1 and PHLPP2 proteins in ESCC tissues. Ectopic overexpression of miR-224 promoted proliferation, migration, and invasion, but suppressed apoptosis of ESCC cells. miR-224 was able to bind to the 3′ untranslated region (3′-UTR) of PHLPP1 and PHLPP2 mRNA to suppress their expression.
The current study demonstrated that miR-224 acts as an oncogenic miRNA in ESCC, possibly by targeting PHLPP1 and PHLPP2.
Esophageal cancer is a lethal disease with poor prognosis. A large percentage of patients with esophageal cancer are diagnosed at the advanced stages of disease [1, 2]. Histologically, esophageal cancer occurs in two major forms, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma, each of which has distinct geographic patterns of incidence and risk factors [3, 4]. Stretching from northern Iran through the central Asian republics to North-Central China, ESCC is the predominant histological subtype, accounting for 90 % of the total esophageal cancer cases . To date, surgery is the only cure option to treat esophageal cancer patients, but this only applies to limited numbers of patients due to their inoperable disease; thus, the overall five-year survival rate for the patients is 14 to 20 % . Although multiple genetic and epigenetic alterations have been detected in ESCC [5, 6], the precise pathogenesis of ESCC remains to be discovered. Molecular markers for early diagnosis and prediction of prognosis or treatment responses are quite limited . Thus, further studies on the targeted prevention and early detection of esophageal cancer could help to limit the lethality of this disease.
microRNA (miRNA) is a class of small-regulatory non-coding RNA molecules with 18 to 22 nucleotides long. It can post-transcriptionally regulate gene expression through pairing with the 3′-untranslated region (UTR) of the targeted messenger RNAs (mRNA) and control translation or induce degradation of target gene. miRNA plays an important role in basic physiological processes in cells, such as cell growth, differentiation, apoptosis, energy metabolism, and immune response . Previous studies demonstrated that aberrant miRNA expression can act as either a tumor suppressor or oncogene [8, 9]. A number of miRNA expression profiling studies have been conducted in ESCC, and the expression of miRNAs, including miR-21, miR-25, and miR-223 have been shown to be altered. These miRNAs could be further evaluated as biomarkers for association with ESCC progression and clinical outcome [9, 10]. Other studies showed that dysregulation of miR-145 and miR-195 was able to modulate ESCC cell viability, proliferation, invasion, and metastasis [8, 11]. In our unpublished study, we identified several differentially expressed miRNAs in ESCC tissues, compared to paired distant normal tissues, using the Agilent microarray and found several high expressed miRNAs, including miR-244. Indeed, miR-224 has been reported to be dysregulated in various human malignancies and can potentially affect many cancer-related cellular processes, including gene transcription, proliferation, differentiation, and cell death [12, 13]. Bioinformatical studies have shown that miR-224 may target PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 and PHLPP2, both of which function as a tumor suppressor by blocking Akt signaling. Down-regulation of PHLPP1 and PHLPP2 proteins has been found in a variety of malignant tumors, including colorectal cancer , prostate cancer , and chronic lymphocytic leukemia (CLL) .
In this study, we first assessed miR-244 expression in esophageal intraepithelial neoplasia biopsies, ESCC tissues, and their matched distant normal tissues, then associated the expression pattern with clinicopathological features from ESCC patients. We also examined the effects of miR-224 expression or inhibition on regulation of ESCC cell viability and mobility and investigated the underlying molecular events in esophageal cancer cells in vitro.
In this study, we collected 103 cases of esophageal patients from General Surgery Department and Digestive Disease Department, The First Affiliated Hospital of Nanjing Medical University (Jiangsu, China), between January 2013 and December 2013. Patients who had received radiotherapy, chemotherapy, or other esophageal surgery before esophagectomy were excluded. Specifically, we obtained 10 pairs of low-grade intra-epithelial neoplasia (LG-IEN) biopsies and their matched distant normal tissues (5 cm away from the lesion), 30 pairs of HG-IEN biopsies and their matched distant normal tissues, and 63 pairs of ESCC tissues and their matched normal esophageal tissues (5 cm away from tumor lesion according to NCCN guideline of esophageal cancer) for this study. Patients with a postoperative pathological result including both IEN and ESCC were included into ESCC group. And only those paitients who had IEN only were included in the IEN group. All tissue specimens were immediately snap-frozen in liquid nitrogen and then stored at −80 °C. This study was approved by the Ethics Committee of the First Affiliated Hospital of Nanjing Medical University, and a written informed consent was obtained from each patient.
RNA isolation and quantitative reverse-transcriptase-polymerase chain reaction (qRT-PCR)
Total cellular RNA was isolated from tissue specimens or cell lines using the Trizol reagent (TaKaRa, Dalian, China), according to the manufacturer’s instructions. For qRT-PCR, 2 μg each of these RNA samples were reversely transcribed into cDNA using PrimeScript RT Master Mix (TaKaRa), and PCR amplification was performed at an initial 95 °C for 5 min and then 40 cycles of 95 °C for 20 s, 60 °C for 20 s, and 70 °C for 10 s in the StepOnePlus™ PCR system (ABI, USA) using SYBR Premix Ex Taq (Takara), according to the manufacturer’s procedures. The qRT-PCR miRNA Primer Set (one RT primer and a pair of qPCR primers for each set) specific for miR-224 was designed and synthesized by RiboBio (Guangzhou, China). U6 small nuclear RNA was used to normalize miR-224 expression. All qRT-PCR amplification was performed in triplicate and repeated at least once. The relative miR-224 expression levels after normalization to U6 small nuclear RNA were calculated using 2-[(Ct of miR-224) – (Ct of U6)]. The increasing fold of miR-224 were expressed relative to the matched normal tissues and calculated using 2-ΔΔCT(ΔΔCT = ΔCTIEN/ESCC-ΔCTNormal). All data after logarithm transition (y = LnX) were applied for the statistical analysis.
Cell lines and culture
Human ESCC cell line TE13 and Eca109 were obtained from Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China) and cultured in Rosewell Park Memorial Institute (RPMI)-1640 medium with 10 % fetal bovine serum (FBS; Invitrogen, Carlsbad, CA, USA) in a humidified incubator with 5.0 % CO2 at 37 °C. To avoid possible effects on gene expression, antibiotic was not used in cell culture.
Transient gene transfection into ESCC cell lines
Cell viability assay
After transfection with aforementioned RNA oligonucleotides, TE13 and Eca109 cells were seeded in 96-well plates at a density of 4000 cells/well and cultured for 24 to 96 h. At the end of each experiment, Cell Counting Kit-8 (Dojindo, Shanghai, China) reagents were added into each well and the plates were incubated for 1.5 h, and the optical density (OD) was then measured at 450 nm using NanoDrop 2000 (Thermo, USA). The experiments were performed in 5 replicates and repeated three times.
Colony formation assay
Forty-eight h after transfection with RNA oligonucleotides, cells were trypsinized and plated on 6-well plates at a density of 300 cells/well and cultured for 10 days. The colonies were then fixed with methanol for 15 min and stained with 0.4 % crystal violet at the room temperature for 30 min. The number of colonies, which were defined as > 50 cells/colony, were counted. The experiments were performed in triplicate and repeated three times.
Flow cytometric apoptosis assay
Forty-eight hours after transfection with RNA oligonucleotides, cells were harvested through trypsinization and washed two times with phosphate buffered saline (PBS). Apoptosis was assessed using a FITC Annexin V Apoptosis Kit (Becton Dickinson, Franklin Lakes, NJ, USA), according to the manufacturer’s instructions. Cells were then analyzed using a flow cytometer (Becton Dickinson) within 1 h of staining using the FL1-H (FITC) and FL2-H (PI) lines.
Tumor cell migration and invasion assay
Tumor cell migration and invasion were assayed using 24-well Transwell plates with 8 mm pore size (Millipore, Bedford, MA, USA). For migration assay, 48 h after transfection with RNA oligonucleotides, ESCC cells were trypsinized, washed, resuspended in 2 % FBS-containing medium, and added to the upper chamber, while 15 % FBS-containing medium was added to the bottom chambers. The Transwell chambers were incubated at 37 °C for 48 h and non-migrating cells were removed by a cotton swab, while the migrated cells were fixed, stained with crystal violet, and counted for ten random fields/chamber. The experiments were conducted in triplicate and repeated three times. Tumor cell invasion assay was the same as the migration assay, except that the membranes were coated with Matrigel (BD) and the Transwell plates were fixed and stained 72 h after the invasion assay.
Using online tools, including miRBase, TargetScan, and miRDB, we found that PHLPP1 and PHLPP2 are potentially targeted by miR-224. The miR-224 binding site is localized between 518 to 524 bp of the PHLPP1 3′-UTR (a total of 1002 bp long) or between 3562 to 3568 bp of the PHLPP2 3′-UTR (3941 bp long). The sequence of PHLPP1 pGL3-3′-UTR-wt (5′-AUAUGGAGACUAACUCCUAGGAGUUGCUUUACUCUGUCAGGUGACUUAAGUCACUGGGAUUCACUAAUUUUCUCUGAGAGAACAGCUG-3′), pGL3-3′-UTR-mut (5′-AUAUGGAGACUAACUCCUAGGAGUUGCUUUACUCUGUCAGUUAUGAUCAGUCACUGGGAUUCACUAAUUUUCUCUGAGAGAACAGCUG-3′), PHLPP2 pGL3-3′-UTR-wt (5′-CCGACUCCCAAUCAUGAAGGCAAGUUAAUCUUUCCAGUUAGUGACUUUUGCCCCAUAGUUGGGGUAAGCACUUVVUAGAUUGAAAA-3′), and pGL3-3′-UTR-mut (5′-CCGACUCCCAAUCAUGAAGGCAAGUUAAUCUUUCCAGUUAUACUGUAUUGCCCCAUAGUUGGGGUAAGCACUUCCUAGAUUGAGAAAA-3′) were generated by Invitrogen-China. Eca109 and TE13 cells were then co-transfected with pGL3-3′-UTR and miR-224 mimic or inhibitor, or their matched miR-negative control. After 24 h transfection, Firefly and Renilla luciferase activity was measured using the Dual Luciferase Assay kit (Promega, Madison, WI, USA), according to the manufacturer’s instructions. The data were normalized against the activity of the Renilla luciferase. The experiments were performed in triplicate and repeated three times.
Protein extraction and Western blot
Tissue specimens and cells were homogenized, and the total cellular protein was extracted using the RIPA Lysis Buffer (Beyotime, Jiangsu, China), according to the manufacturer’s instructions. Protein concentration was measured by the BCA method (Beyotime). Western blot was performed using anti-phospho-AKT, anti-AKT, anti-GAPDH (Cell Signaling Technology, Danvers, MA, USA), anti-PHLPP1, and anti-PHLPP2 (Abcam, Cambridge, MA, USA) antibodies. The relative levels of protein expression were quantified by densitometric scanning (Image J Software, NIH, Bethesda, MD, USA), and the relative gray values of protein levels were calculated based on the band intensity of protein of interest divided by the band intensity of loading control.
Seventy-two h after gene transfection, Eca109 cells were fixed in 4 % paraformaldehyde for 15 min at the room temperature, washed three times in PBS, and incubated for 60 min at the room temperature in a blocking solution (Beyotime). The primary antibody (anti-PHLPP1 and anti-PHLPP2 from Abcam) in the blocking reagent was added and incubated overnight at 4 °C. The next day, the cells were washed with PBS for three times, and the fluorescent probe conjugated secondary antibody (Jackson ImmunoResearch, USA) was added to the cells. The cells were further incubated for 60 min at the room temperature and then washed three times in PBS. Cell nucleus was counterstained with DAPI (Beyotime). Photos were then taken using a Nikon Fluorescence microscope.
The data were summarized as mean ± S.D. and analyzed using Student’ t-test, Chi-square test, mono factor analysis of variance, and the correlation analysis with SPSS 17.0 software (SPSS, Chicago, IL, USA). A p-value less than 0.05 was considered to be statistically significant.
Overexpression of miR-224 is in esophageal intraepithelial neoplasia and ESCC tissue specimens
Association of miR-224 expression with clinicopathological features from ESCC patients
Tumor length (cm)
Ectopic expression of miR-224 changed phenotypes of ESCC cell in vitro
Next, we altered miR-224 expression in esophageal cancer cell lines. As shown in Fig. 1d, transfection with miR-224 mimics or inhibitor significantly up- or down-regulated the level of miR-224 expression in Eca109 and TE13 cells compared to the control oligonucleotides-transfected cells.
miR-224 directly targets tumor suppressor gene PHLPP1 and PHLPP2 in ESCC cells
Ectopic expression of miR-224 affected the Akt signaling in ESCC cells
To explore the possible underlying molecular mechanisms of miR-224 action in ESCC cell lines, we analyzed the downstream signals of PHLPP1 and PHLPP2. As shown in Fig. 5a, phosphorylation levels of AKT protein was increased in miR-224-overexpressing ESCC cells, whereas anti-miR-224 suppressed the levels of phosphorylated AKT protein compared to the negative control.
Down-regulated PHLPP1 and PHLPP2 expression associated with miR-224 expression in ESCC tissues
In the current study, we first assessed miR-244 expression in esophageal IEN biopsies, ESCC tissues, and their matched distant normal tissues, and associated the expression pattern with clinicopathological features from ESCC patients. We also investigated the effects of miR-224 expression or inhibition on regulation of ESCC cell viability and invasion capacity, and determined the underlying molecular mechanisms in esophageal cancer cells in vitro. We found that miR-224 was up-regulated in esophageal IEN and ESCC tissue specimens compared to that of the matched distant normal tissues, and miR-224 expression was associated with aggressive characteristics of IEN and ESCC. Furthermore, ectopic overexpression of miR-224 promoted proliferation, migration, and invasion, but suppressed apoptosis of ESCC cells in vitro. miR-224 was able to bind to PHLPP1 and PHLPP2 3′-UTR and suppressed their expression and may subsequently induced activity of the AKT signaling, while the levels of PHLPP1 and PHLPP2 proteins were associated with miR-224 expression in ESCC tissues. Our current data indicates that miR-224 is an oncogenic miRNA and targets expression of PHLPP1 and PHLPP2 proteins in ESCC.
Nevertheless, it should be noted that miR-224 can be up-regulated or down-regulated in different types or subtypes of cancer. For example, miR-224 expression was frequently up-regulated in hepatocellular carcinoma , colorectal cancer , medulloblastoma , thyroid cancer , pancreatic ductal adenocarcinoma , renal cancer , cervical cancer , and glioma . In contrast, down-regulation of miR-224 has been observed in prostate cancer , ovarian cancer , giant cell tumor , and oral cancer . These data suggest that miR-224 can function as an oncogene or tumor suppressor through regulating the expression of different target genes. For example, in hepatocellular carcinoma, ectopic overexpression of miR-224 significantly down-regulated HOXD10 expression and promoted cell migration and invasion , whereas inhibition of miR-224 expression enhanced cell migration and invasion of prostate cancer cells through direct regulation of oncogenic TPD52 . In support of the tumor-promoting role of miR-224 in ESCC, our current data showed that miR-224 was up-regulated in esophageal IEN and ESCC tissue specimens compared to that of the matched distant normal tissues, and miR-224 expression was associated with aggressive characteristics of IEN and ESCC. These data further confirmed that miR-224 can function as an oncogene by regulating the expression of PHLPP1 and PHLPP2 proteins.
Furthermore, our current data also showed that ectopic overexpression of miR-224 promoted proliferation, migration, and invasion, but suppressed apoptosis of ESCC cells in vitro, which is consistent with the data on HCC . Importantly, our current study further confirmed that PHLPP1 and PHLPP2 are two target genes of miR-224. Both of PHLPP1 and PHLPP2 proteins contain each of a PH domain, leucine-rich repeat, phosphatase domain, and PDZ-binding motif . As tumor-suppressor phosphatases, PHLPP1 and PHLPP2 proteins act to suppress cell survival pathways. They can directly dephosphorylate a conserved regulatory site (termed the hydrophobic motif) of Akt protein, protein kinase C, and S6 kinase. In turn, these phosphatases block signaling of these pro-survival kinases, and promote apoptosis and suppress tumor growth [30, 31]. A number of studies showed altered expression of PHLPP1 and PHLPP2 and their functions in various malignancies [32, 33]. Indeed, a previous study showed expression and association between miR-224 and PHLPPs in colorectal cancer . Another study reported by Cai et al.  suggested that PHLPP2 was a bona fide target gene of miR-205 and associated the up-regulation of miR-205 with cell growth and vascularization. Our current data further demonstrated that the loss of PHLPP1 and PHLPP2 expression occurred in ESCC tissue samples and their expression was associated with miR-224 expression in ESCC tissues. These data revealed the mechanisms responsible for PHLPP expression, because to date, little is known regarding regulation of PHLPP expression in different human cells .
However, our current study is limited to proof-of-principle and further investigations are needed to understand the role of miR-224 in esophageal cancer and clarify how miR-224 regulates expression of PHLPP1 and PHLPP2 proteins during esophageal cancer compared to other cancer pathogenesis.
In summary, our current study showed that miR-224 up-regulation could promote ESCC development, possibly through inhibiting PHLPP1 and PHLPP2 expression, indicating that miR-224 has oncogenic activity in ESCC. These findings may not only increase our understanding of ESCC development and progression, but may also help us to develop a novel therapeutic strategy for ESCC.
We thank all patients who participated in this study. This study was supported in part by a grant from the College graduate research and innovation projects of Jiangsu Province (#CXZZ11_0705). We thank Medjaden Bioscience Limited for assisting in the preparation of this manuscript.
- Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.View ArticlePubMedGoogle Scholar
- Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.View ArticlePubMedGoogle Scholar
- Wheeler JB, Reed CE. Epidemiology of esophageal cancer. Surg Clin North Am. 2012;92(5):1077–87.View ArticlePubMedGoogle Scholar
- Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598–606.View ArticlePubMedPubMed CentralGoogle Scholar
- Toh Y, Egashira A, Yamamoto M. Epigenetic alterations and their clinical implications in esophageal squamous cell carcinoma. Gen Thorac Cardiovasc Surg. 2013;61(5):262–9.View ArticlePubMedGoogle Scholar
- Hasan R, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, et al. Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis. BMC Cancer. 2014;14:2.View ArticlePubMedPubMed CentralGoogle Scholar
- Maqbool R, Hussain MU. MicroRNAs and human diseases: diagnostic and therapeutic potential. Cell Tissue Res. 2014;358(1):1–15.View ArticlePubMedGoogle Scholar
- Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu H, et al. Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett. 2013;587(21):3471–9.View ArticlePubMedGoogle Scholar
- Li P, Mao WM, Zheng ZG, Dong ZM, Ling ZQ. Down-regulation of PTEN expression modulated by dysregulated miR-21 contributes to the progression of esophageal cancer. Dig Dis Sci. 2013;58(12):3483–93.View ArticlePubMedGoogle Scholar
- Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. Mol Biol Rep. 2014;41(3):1257–66.View ArticlePubMedGoogle Scholar
- Wang F, Xia J, Wang N, Zong H. miR-145 inhibits proliferation and invasion of esophageal squamous cell carcinoma in part by targeting c-Myc. Onkologie. 2013;36(12):754–8.PubMedGoogle Scholar
- Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, et al. miR-224 promotion of cell migration and invasion by targeting Homeobox D 10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29(4):835–42.View ArticlePubMedGoogle Scholar
- Liao WT, Li TT, Wang ZG, Wang SY, He MR, Ye YP, et al. microRNA-224 promotes cell proliferation and tumor growth in human colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res. 2013;19(17):4662–72.View ArticlePubMedGoogle Scholar
- Liu J, Weiss HL, Rychahou P, Jackson LN, Evers BM, Gao T. Loss of PHLPP expression in colon cancer: role in proliferation and tumorigenesis. Oncogene. 2009;28(7):994–1004.View ArticlePubMedGoogle Scholar
- Mulholland DJ, Tran LM, Li Y, Cai H, Morim A, Wang S, et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell. 2011;19(6):792–804.View ArticlePubMedPubMed CentralGoogle Scholar
- O'Hayre M, Niederst M, Fecteau JF, Nguyen VM, Kipps TJ, Messmer D, et al. Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL). Leukemia. 2012;26(7):1689–92.View ArticlePubMedPubMed CentralGoogle Scholar
- Wang Y, Lee CG. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics. 2011;3(2):235–43.View ArticlePubMedGoogle Scholar
- Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. Up-regulation of miR-224 promotes cancer cell proliferation and invasion and predicts relapse of colorectal cancer. Cancer Cell Int. 2013;13(1):104.View ArticlePubMedPubMed CentralGoogle Scholar
- Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol. 2013;15(12):1644–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Pai R, Nehru GA, Samuel P, Selvan B, Kumar R, Jacob PM, et al. Discriminating thyroid cancers from benign lesions based on differential expression of a limited set of miRNA using paraffin embedded tissues. Indian J Pathol Microbiol. 2012;55(2):158–62.View ArticlePubMedGoogle Scholar
- Mees ST, Mardin WA, Sielker S, Willscher E, Senninger N, Schleicher C, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol. 2009;16(8):2339–50.View ArticlePubMedGoogle Scholar
- Lichner Z, Mejia-Guerrero S, Ignacak M, Krizova A, Bao TT, Girgis AH, et al. Pleiotropic action of renal cell carcinoma-dysregulated miRNAs on hypoxia-related signaling pathways. Am J Pathol. 2012;180(4):1675–87.View ArticlePubMedGoogle Scholar
- Shen SN, Wang LF, Jia YF, Hao YQ, Zhang L, Wang H. Upregulation of microRNA-224 is associated with aggressive progression and poor prognosis in human cervical cancer. Diagn Pathol. 2013;8:69.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu S, Wang S, Geng S, Ma S, Liang Z, Jiao B. Upregulation of microRNA-224 confers a poor prognosis in glioma patients. Clin Transl Oncol. 2013;15(7):569–74.View ArticlePubMedGoogle Scholar
- Prueitt RL, Yi M, Hudson RS, Wallace TA, Howe TM, Yfantis HG, et al. Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate. 2008;68(11):1152–64.View ArticlePubMedPubMed CentralGoogle Scholar
- Christenson LK. MicroRNA control of ovarian function. Anim Reprod. 2010;7(3):129–33.PubMedPubMed CentralGoogle Scholar
- Fellenberg J, Saehr H, Lehner B, Depeweg D. A microRNA signature differentiates between giant cell tumor derived neoplastic stromal cells and mesenchymal stem cells. Cancer Lett. 2012;321(2):162–8.View ArticlePubMedGoogle Scholar
- Scapoli L, Palmieri A, Lo Muzio L, Pezzetti F, Rubini C, Girardi A, et al. MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 2010;23(4):1229–34.PubMedGoogle Scholar
- Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, et al. Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett. 2014;588(10):1973–82.View ArticlePubMedGoogle Scholar
- Brognard J, Sierecki E, Gao T, Newton AC. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell. 2007;25(6):917–31.View ArticlePubMedGoogle Scholar
- Gao T, Furnari F, Newton AC. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005;18(1):13–24.View ArticlePubMedGoogle Scholar
- Agarwal NK, Zhu X, Gagea M, White 3rd CL, Cote G, Georgescu MM. PHLPP2 suppresses the NF-kappaB pathway by inactivating IKKbeta kinase. Oncotarget. 2014;5(3):815–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Dong L, Jin L, Tseng HY, Wang CY, Wilmott JS, Yosufi B, et al. Oncogenic suppression of PHLPP1 in human melanoma. Oncogene. 2013;33(39):4756–66.View ArticlePubMedGoogle Scholar
- Cai J, Fang L, Huang Y, Li R, Yuan J, Yang Y, et al. miR-205 targets PTEN and PHLPP2 to augment AKT signaling and drive malignant phenotypes in non-small cell lung cancer. Cancer Res. 2013;73(17):5402–15.View ArticlePubMedGoogle Scholar
- Newton AC, Trotman LC. Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol. 2014;54:537–58.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.